Market research
N4P.LSE N4 Pharma Plc
LSE GBP Healthcare
Latest close
As of 16 Jun 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 12
- Dividend yield
- Not available
- Beta
- 0.29
Profile
Instrument facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BYW8QM32
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 12
- Dividend yield
- Not available
- Beta
- 0.29
About
About N4 Pharma Plc
N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.
Research context
N4 Pharma Plc appears in PyInvesting’s London Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the N4P.LSE discussion.
5 years, 6 months ago
N4 Pharma Plc is currently in a long term uptrend where the price is trading 13.2% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Its net income has dropped by 0.0% to $-162K since the same quarter in the previous year.
Finally, its free cash flow fell by 421.6% to $-475K since the same quarter in the previous year.
Based on the above factors, N4 Pharma Plc gets an overall score of 2/5.